Response to commentary on “pembrolizumab in gestational trophoblastic neoplasia: systematic review and meta-analysis with sub-group analysis of potential prognostic factors”
Marcio Barcellosa,b,1, Antonio Bragaa,b,c,1,
, Matheus Machado Rechd, Solange Artimos de Oliveirab, Jose Mauro Madid, Sue Yazaki Sune, Jorge de Rezende-Filhoa, Kevin M. Eliasf, Neil S. Horowitzf, Ross S. Berkowitzf
Corresponding author
antonio.braga@ufrj.br
Corresponding author at: Rio de Janeiro Trophoblastic Disease Center, Maternidade Escola da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Corresponding author at: Rio de Janeiro Trophoblastic Disease Center, Maternidade Escola da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
a Rio de Janeiro Trophoblastic Disease Center, Maternidade Escola da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
b Postgraduate Program in Medical Sciences, Faculdade de Medicina da Universidade Federal Fluminense, Rio de Janeiro, RJ, Brazil
c Postgraduate Program in Applied Health Sciences, Universidade Vassouras, Vassouras, RJ, Brazil
d Caxias do Sul Trophoblastic Disease Center, Faculdade de Medicina da Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil
e Department of Obstetrics. Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
f New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Read
527
Timeswas read the article
224
Total PDF
303
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 13 | 8 | 21 |
| 2025 11 | 47 | 40 | 87 |
| 2025 10 | 27 | 44 | 71 |
| 2025 9 | 52 | 70 | 122 |
| 2025 8 | 72 | 31 | 103 |
| 2025 7 | 91 | 31 | 122 |
| 2025 6 | 1 | 0 | 1 |